(Disclaimer: This article is only for scientific purposes, in order to protect patient privacy, the relevant information in the following content has been processed) Abstract: Viral hepatitis B, commonly known as hepatitis B, is one of the common chronic liver diseases, this article describes the treatment experience of a patient with hepatitis B who had severe impairment of liver function, and the patient’s condition recovered well after standardized diagnosis and treatment such as antiviral, hepatoprotective and anti-inflammatory treatment, and the treatment of hepatitis B should be focused on standardization and The treatment of hepatitis B should focus on standardization and individualization, and most of the hepatitis B can be stabilized for a long time after standardized treatment. Basic information] Male, 50 years old [Disease type] Hepatitis B [Hospital] The First Affiliated Hospital of Henan University [Time of consultation] October 2021 [Treatment plan] Oral medication (entecavir dispersible tablets, silymarin capsules) + intravenous infusion (compound glycyrrhizic acid glycoside injection, reduced glutathione for injection) [Treatment cycle] Hospitalization for 2 weeks, discharge follow-up for half a year [Treatment effect The condition gradually returned to normal, long-term oral entecavir dispersible tablets antiviral treatment, repeated review of liver disease condition stabilization I. Initial consultation The patient was physically fit and had no history of chronic diseases. 1 month ago, the patient was treated for poor appetite in the local hospital, and symptomatic treatment was given according to gastritis, which was ineffective without any obvious improvement in symptoms. 1 week ago, the patient underwent gastroscopy, and the preoperative screening for infectious disease markers revealed hepatitis B. The results showed that gammaglutamyltransferase (GGT) was the highest in the world, with the highest in the world. Liver function tests showed an ALT of 973 U/L, AST of 453 U/L, and GGT of 246 U/L, and hepatitis B V showed that the patient was triple positive. The patient came to our outpatient clinic for retesting of alanine aminotransferase (AAT) was 1198 U/L, glutamate aminotransferase (GGT) was 682.9 U/L, glutamyltransferase (GGT) was 313.8 U/L, and the quantitative detection of hepatitis B virus DNA was 1.27E+06IU/ml. liver ultrasonography was performed, and the results suggested diffuse intrahepatic injury, roughness of gallbladder wall, and the elasticity of liver was detected at 11.5Kpa. Since the patient had no other obvious symptoms, he did not feel that his condition was serious, but he was very hesitant when he saw the high test results, and with my patient explanation, he finally agreed to be hospitalized. After admission to the hospital, relevant auxiliary examinations were perfected, other common causes of liver disease were excluded, and careful inquiry of medical history revealed that the patient’s mother and an elder brother also suffered from hepatitis B, and the patient’s mother was detected with cirrhosis of the liver five years ago, which indicated that the patient’s hepatitis B was not a recent infection, but probably had been infected since childhood. In accordance with the recommendations in the Guidelines for the Prevention and Control of Chronic Hepatitis B (2019 edition), antiviral therapy was recommended, and after patient communication with the patient, informing him of his current condition and the necessity of treatment, the patient finally accepted the antiviral therapy regimen. At the same time, the patient was given intravenous application of compound glycyrrhizin injection and reduced glutathione for injection. After the above treatments, the liver function was reviewed at 1 week of treatment, and the alanine aminotransferase (ALT) was 688.10 U/L, and the glutamine aminotransferase (AST) was 226.30 U/L, and basically recovered to normal at 2 weeks, in which the alanine aminotransferase (ALT) was 93.8 U/L, and the glutamine aminotransferase (AST) was 18 U/L. III. Therapeutic effect After 2 weeks of hospitalization, the patient’s condition After 2 weeks of hospitalization, the patient’s condition stabilized and reached the discharge standard. After discharge, the patient was instructed to continue oral antiviral treatment with entecavir dispersible tablets and liver protection drugs, such as silymarin capsules, etc. After 3 months, the liver function test was repeated, which showed that the patient’s liver function was still normal and the hepatitis B DNA was below the lower limit of detection, so the liver protection drugs were discontinued, and antiviral treatment was carried out with entecavir dispersible tablets alone. Six months after discharge, liver function, liver ultrasound, quantitative detection of hepatitis B DNA and other indicators, the condition has been stabilized, but antiviral treatment should be continued, and should be repeated every 6 months. Seeing this result, patients feel happy from the bottom of their heart, no longer need to worry about the recurrence of hepatitis B. Precautions: We are glad that the patient’s condition has gradually returned to normal and stabilized after treatment. However, when the patient’s hepatitis B activity is controlled and stabilized, the following aspects should be noted in life and diet: 1, the core treatment of hepatitis B is antiviral therapy, long-term treatment should be adhered to, and should not be stopped at will; 2, adhere to the regular rechecking of liver function, hepatitis B DNA, liver ultrasound, alpha-fetoprotein and other indexes, to monitor the condition changes; 3, encourage to quit drinking and smoking, do not stay up too late, and keep a positive and optimistic state of mind; 4, rationalize the diet, and increase the amount of alcohol and tobacco. Encourage people to have a reasonable diet, eat more fresh fruits and vegetables, participate in sports activities, and consult the doctor in time if they feel unwell. V. Personal Insight Hepatitis B has an insidious history and often lacks typical clinical symptoms, and even lacks symptoms when liver function has been severely impaired. Therefore, all patients with hepatitis B should not decide the timing of treatment based on the presence or absence of uncomfortable symptoms, and those with family history should pay more attention to it. Instead, all patients with hepatitis B should have regular rechecks of liver function, hepatitis B DNA, liver ultrasound, and alpha-fetoprotein to make a comprehensive judgment of their condition and to detect possible conditions in a timely manner. The patient in this case has been suffering from hepatitis B for many years, but fortunately, his condition has gradually returned to normal after treatment, and he should insist on regular review of liver function, quantitative test of hepatitis B DNA, liver ultrasound, alpha-fetoprotein and other tests in order to monitor the changes of his condition.